Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
July 31, 2007

Laureate to Manufacture Enobia Pharma’s Candidate against Hypophosphatasia

  • Laureate Pharma entered into a cGMP contract manufacturing agreement with Enobia Pharma, which is engaged in the development of enzyme replacement therapy for the treatment of hypophosphatasia.

    Laureate will produce Enobia Pharma’s fusion protein for this rare and sometimes fatal metabolic bone disease characterized by skeletal hypomineralization. Enobia anticipates initiating clinical studies in this lead program  in the summer of 2008.

  • You’re all set! Thank you for subscribing to GEN Highlights.